[go: up one dir, main page]

MD478G2 - Method of ulcer treatment to women with hyperprolactinemia - Google Patents

Method of ulcer treatment to women with hyperprolactinemia

Info

Publication number
MD478G2
MD478G2 MD96-0032A MD960032A MD478G2 MD 478 G2 MD478 G2 MD 478G2 MD 960032 A MD960032 A MD 960032A MD 478 G2 MD478 G2 MD 478G2
Authority
MD
Moldova
Prior art keywords
days
day
evening
proposed method
method consists
Prior art date
Application number
MD96-0032A
Other languages
Romanian (ro)
Russian (ru)
Other versions
MD478F1 (en
Inventor
Maria Rusu
Зинаида АНЕСТИАДИ
Константин БАБЮК
Original Assignee
Государственный Медицинский И Фармацевтический Университет "Nicolae Testemitanu" Республики Молдова
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Государственный Медицинский И Фармацевтический Университет "Nicolae Testemitanu" Республики Молдова filed Critical Государственный Медицинский И Фармацевтический Университет "Nicolae Testemitanu" Республики Молдова
Priority to MD96-0032A priority Critical patent/MD478G2/en
Publication of MD478F1 publication Critical patent/MD478F1/en
Publication of MD478G2 publication Critical patent/MD478G2/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

The invention relates to the medicine, particularly, to the gastroenterology.The summary of the proposed method consists in the fact that in addition to the limited regimen, diet, antisecretory and antibacterial drugs bromocryptine is administered according to the following scheme: the first 3 days in the evening 1,25-2,5 mg, the 4-6th days in the morning and evening 1,25-2,5 mg, the 7-9th days 1,25-2,5 mg 3 times a day and beginning with the 10th day 2,5-3,75 mg 3 times a day till the disappearance of the ulcer chemical symptoms and normalization of prolactin high concentration in the blood stream. After that the bromocryptin doze is constantly reduced: 3 days - 1,25-2,5 mg 3 times a day, the following 2-3 days - 1,25-2,5 mg 2 times a day and the last 3 days - 1,25-2,5 mg in the evening.The technical result of the proposed method consists in the reduction of relapses amount and acceleration of gastroduodenal ulceros healing.
MD96-0032A 1996-02-20 1996-02-20 Method of ulcer treatment to women with hyperprolactinemia MD478G2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
MD96-0032A MD478G2 (en) 1996-02-20 1996-02-20 Method of ulcer treatment to women with hyperprolactinemia

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MD96-0032A MD478G2 (en) 1996-02-20 1996-02-20 Method of ulcer treatment to women with hyperprolactinemia

Publications (2)

Publication Number Publication Date
MD478F1 MD478F1 (en) 1996-10-31
MD478G2 true MD478G2 (en) 1997-05-31

Family

ID=19738790

Family Applications (1)

Application Number Title Priority Date Filing Date
MD96-0032A MD478G2 (en) 1996-02-20 1996-02-20 Method of ulcer treatment to women with hyperprolactinemia

Country Status (1)

Country Link
MD (1) MD478G2 (en)

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Терапевтический архив, т. 62, № 2, 1990 г., Медицина, М., А. С. Логинов "Язвенная болезнь", с. 7-28. *
Терапевтический архив, т. 63, № 2,1991 г., Медицина, М., П.Я Григорьев, В.А. Исаков "Этиологические и патогенетические подходы к лечению язвенной болезни", c. 30. *

Also Published As

Publication number Publication date
MD478F1 (en) 1996-10-31

Similar Documents

Publication Publication Date Title
UA37244C2 (en) Method for treating or preventing clinical disorders curable with progesterone in female patients
EP0373744A3 (en) Use of nalmefene or naltrexone in the treatment of autoimmune diseases
EP0377272A3 (en) Use of nalmefene or naltrexone in the manufacture of a medicament for the treatment of inflammation in an arthritic disease or associated inflammatory diseases
ATE67677T1 (en) MEDICATIONS FOR ORAL ADMINISTRATION CONTAINING 10 TO 240 MG OF DIHYDROPYRIDINE IN A SINGLE DOSE.
Loiudice et al. Treatment of acute alcoholic pancreatitis: the roles of cimetidine and nasogastric suction.
GB8817015D0 (en) Method of treatment
GR3034186T3 (en) 3,4-diarylchromans for treatment of dermatitis
Sullivan et al. Enkephalin in peripheral neuroendocrine tumours
ATE102830T1 (en) METHOD OF TREATMENT OF INTERSTITIAL BLADDER INFLAMMATION.
EP1294375A4 (en) Method of treatment of seborrheic dermatitis
FR2437834A1 (en) L-serine or glycine for treatment of cerebral deficiencies - such as mongolism and general mental debility, etc.
AU573262B2 (en) Covalently bound heparin-antithrombin iii complex
MD478G2 (en) Method of ulcer treatment to women with hyperprolactinemia
EP0302714A3 (en) Pharmaceutical composition for treatment of bone-wasting diseases
Cerklewski Influence of dietary magnesium on fluoride bioavailability in the rat
US5766640A (en) Simutaneous treatment of osteoporosis and hypertension
Sweany et al. A preliminary report on the use of para-amino salicylic acid in the treatment of pulmonary tuberculosis
RU96112591A (en) METHOD FOR TREATING CHRONIC ALCOHOLISM
Mazure Comparative efficacy of misoprostol and cimetidine in the treatment of acute duodenal ulcer: Results of major studies
Subotičanec Vitamin C status in schizophrenia
Bell et al. Conversion from troglitazone to rosiglitazone
Beckingham et al. Acute thrombocytopenia after De-Nol
Mungavin et al. Comparison of two dosage regimens of trazodone(molipaxin) in the treatment of depression. A multicentre general practice study.
Johannessen et al. 1-and 4-week cimetidine treatment for duodenal ulcer
Graham et al. Double-blind Multicenter Comparison of 1,200 mg. and 1,000 mg. Cimetidine in Hospitalized and Ambulatory Duodenal Ulcer Patients.

Legal Events

Date Code Title Description
FG3A Granted patent for invention
IF99 Valid patent on 19990615

Free format text: EXPIRES: 20160220